Not a bad read overall but yes very contingent on the authorities, I liked how ALL of the MPS patients in Brazil opt for further treatment, that's a good sign that the like the drug and are deriving benefit from it.
"Following the conclusion of Paradigm’s successful multi-centre phase 2 clinical trial,
randomising 13 MPS VI participants to iPPS or placebo, all 13 participants have elected to
continue or commence (for the placebo group) ongoing iPPS treatment".
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-7
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $68.29M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.5¢ | 19.5¢ | $142.7K | 723.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 45775 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 18290 | 2 |
View Market Depth
| Last trade - 16.10pm 09/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |